| Generic name | Decitabine and cedazuridine |
| Brand name(s), other common name(s) | Inqovi® |
| Drug type | Combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor |
| How the drug is given | Tablet, for oral use |
Indications and Usage
Inqovi is FDA approved for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Side effects needing medical attention
Most common adverse reactions are fatigue, constipation, hemorrhage, muscle pain or muscle ache (myalgia), mucositis, joint pain (arthralgia), nausea, difficulty breathing (dyspnea), diarrhea, rash, dizziness, febrile neutropenia, swelling caused by excess fluid trapped in the body's tissues (edema), headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and transaminase increased.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.